Smarter Therapies. Better Lives.
next-generation biotherapeutics
At Protomer, we believe that the future of medicine lies in smarter medicines, so we built a company to invent them.
We are engineering the next generation of responsive biotherapeutics
Founded in 2015 and based in Pasadena, California, Protomer is engineering next-generation responsive biotherapeutics that can sense molecular activators in the body. The company’s proprietary chemical biology-based Molecular Evolution of Peptide Sensors (MEPS) platform enables the development of therapeutic peptides and proteins with tunable activity that can be controlled using small molecules.
Protomer has used this approach toward advancing a portfolio of therapeutic candidates, including glucose-responsive insulin receptor agonists that can sense sugar levels in the blood and automatically adjust their activity as needed.
